AntiEpileptic Drugs
New advice on switching between different manufacturers’ products for a particular drug
Different antiepileptic drugs (AEDs) vary considerably in their characteristics, which influences the risk of whether switching between different manufacturers’ products of a particular drug may cause adverse effects or loss of seizure control. AEDs have been divided into three risk-based categories to help healthcare professionals decide whether it is necessary to maintain continuity of supply of a specific manufacturer’s product. Read more via the PDF link below.
Sodium Valproate
Special reminder on risk of neurodevelopmental delay in children following maternal use—not for use in pregnancy
There is new evidence on neurodevelopmental delay in children following maternal use of sodium valproate. A European review is underway to evaluate all currently available evidence on the association between fetal valproate exposure and neurodevelopmental delay or autism spectrum disorder. Healthcare professionals are reminded that sodium valproate should not be used during pregnancy and in women of childbearing potential unless clearly necessary. Read more via the PDF link below.
Full PDF; read and download the MHRA monthly newsletter
Drug Safety Update November 2013 (Volume 7, Issue 4)
For Related Posts, see our Tags:
AEDs – Epilepsy – Drugs – Pregnancy – Topiramate – Valproate